To explore the management of diabetes from a pharmacy perspective and engaging patients in self-management. Methods: A search was made of international peer-reviewed literature in PubMed, Medline, Cochrane Library and the grey literature. This document provides a review of a relevant literature including a general overview of diabetes mellitus, therapeutic goals, pharmacologic and lifestyle treatment. The epidemiology of diabetes was explored, and an overview of new approaches for treatment and management of diabetes mellitus collated. Results: The search yielded studies and information that met the inclusion criteria. Pharmacological and lifestyle management, diabetes education and knowledge, and the prevalence of diabetes were also documented. Conclusion: Research examining the role of healthcare providers as diabetes educators and exploring the needs of patients with diabetes is of importance to optimize health outcomes and minimize costs related to treatment and complications.
INTRODUCTION
Diabetes Mellitus is a group of metabolic disorders characterized by hyperglycaemia which is associated with chronic complications including microvascular, macrovascular, and neuropathic disorders. Hyperglycaemia can result from defects in insulin secretion, insulin action or both 1, 2 . Chronic hyperglycaemia in diabetes is associated with damage to or failure of the eyes, kidneys, nervous system, heart, and blood vessels 2, 3 . Diabetes mellitus is a common chronic disease which, as a result of increase in obesity, changing lifestyles, and an ageing population, is growing globally 4 .
In 2013, it has been estimated that 347 million people have diabetes worldwide 5 . The high prevalence of obesity, has led to new cases of diabetes Type 2 early in life, which is becoming common in children as well as teenagers 6 . The less common type of the disease is Type 1 diabetes and is an autoimmune disease. In more than 90% of those affected it is characterized by beta-cell destruction that usually leads to absolute insulin deficiency, and the rest is idiopathic 3, 7 .
Diabetes is associated with substantial morbidity and mortality, and has significant impact on individuals and their families 3, 8 . The onset of macrovascular and microvascular complications lowers quality of life with an increased burden of illness and the costs of managing the specified complications of diabetes over time 2, 3 .
Review of the Literature

Search Strategy
A literature search was performed, from 2013 to 2014 in Australia, to retrieve information on evidenced-based diabetes care. Search terms used included type 2 diabetes mellitus, education, patients, needs, counselling, adults, knowledge, nutrition, and exercise. The information included in this review was extracted from the PubMed, Medline and Cochrane Library databases and the grey literature wh academics, b formats, but publishers 9 , unpublished Sydney. 10 .
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Non-pharm utritional ther een done that eduction and esult in impro n better patien f life 8, 14 . (Figure 1 ) for meal planning were covered. This included information about the five food groups (vegetables, starches, meats and other types of proteins, dairy, and fruits) 16 . The intervention in this study consisted of meal planning education in three different settings that are at home, supermarket, and restaurant settings 16 . Participants were also trained to know how to make a healthy meals which consisted of the specified allowed amount of each of the five components for each meal during the day 16 . As a result, there were significant increases in daily fruit (p=0.02) and vegetable consumption (p=0.01) 16 .
Diabetic patients are advised to combine the best choices from both food habits of Mediterranean and Western food in which a well-organized meal plan will consist mainly of high fibre carbohydrates (e.g. whole grain breads and cereals), vegetables and fruits, being low in fat and provide adequate amount of needed protein for healthy lifestyle pattern 15 . Overweight patients (with body mass index greater than 25 kg/m 2 ) should reduce their total calorie intake to aid in weight reduction 17 . A healthy diabetic diet should typically include less than 10 % of its energy in the form of saturated fat (less than 8% if hyperlipidaemic), less than one third from all fats, and 50 to 60% carbohydrate which is mostly complex high fibre 17 . Moreover, sugar intake should be limited to about 25 g/day and sodium content to be less than 6 g/day for diabetic patients who are not hypertensive and to lower than 3 g/day if the patient has hypertension 17 . Protein intake should be between 11-35 g/day for health diabetic nutrition 8 .
Regular physical activity has been shown to significantly improve the health outcomes for people with diabetes 18, 19 . Physically active patients with diabetes have been shown to have lower rates of mortality and cardiovascular heart disease 19, 20 . Regular exercise supports in maintaining good blood glucose control which in turn helps in decreasing the risks of developing diabetes complications (e.g. neuropathy and nephropathy) 18 . Exercise can also enhance quality of life and reduce stress, anxiety and depression 18, 21 . Encouraging people to exercise should be considered one of the essential components of diabetes care. Although researchers have demonstrated the importance of exercise as a component of diabetes management, it remains underused 19 .
Regular aerobic exercise has been shown to improve blood lipid profiles, blood pressure and resting heart rates, body composition and glycaemic control in addition to reducing serum cholesterol 18, 19 . Aerobic exercise aids in weight reduction 18 . Guidelines recommend that aerobic activity should be performed for at least 30 minutes at a moderate intensity on most, if not all days of the week with no more than 72 hours between exercise sessions 19 . If weight loss is a desired outcome, then one hour of exercise or more is recommended 18, 19 . It is often hard for the majority of people to begin at this level; thus the recommended exercise regimen should firstly begin at a level the patient could manage, with the aim of gradually increasing exercise duration and intensity as the patient progresses 19 . Exercise could include activities such as walking, swimming or cycling 19 . However, the type of exercise will depend on the patient's safety. The importance of suitable foot care and comfortable, well-fitting footwear during physical activity needs to be stressed, especially if the patient has neuropathy, vascular disease, abnormal foot structure, and/or is present with a history of previous foot ulcer(s) 18, 21 . Healthy life style would include, in addition to diet and exercise, self-measurement of blood glucose concentrations at home, and recognizing, preventing and managing hypoglycaemia 15 . Looking after the feet to aid in managing skin breakage, and self-managing during illness or infection, as well as knowing when to go to the doctor are also important issues to consider in maintaining healthy life style 15, 17 . Tests the doctor should perform include blood pressure, foot examination, HbA 1C to be repeated every 3 months if trying to improve diabetes management in the patient or in a duration of 6-12 months if stability of disease is achieved, cholesterol and triglycerides test to be repeated every 12 months, kidney tests which would be repeated every 12 months and eye examination every 12 months 15, 17 . Insulin injection devices and the correct process of injection, and timing, frequency, how and cautions of taking oral hypoglycaemic agents are important part of patient education that will aid in improving the clinical, biologic and quality of life outcomes in diabetic persons 8, 14, 17 . Figure 2 : Impact of Self-Management Education Intervention (adapted from http://www.thecommunityguide.org/diabetes/dm-AJPM-evrev-incr-DSME-comm.pdf)
Pharmacological Management
Currently eight different classes of oral hypoglycaemic agents (Table 1) are present in addition to insulin ( Metformin should be used with caution in people with hepatic or cardiac disease and in patients with a heavy alcohol intake and stopped if the patient develops acute illness, due to the risk of lactic acidosis 17, 18 . When used alone, metformin rarely causes hypoglycaemia 8, 18 .
However, when insulin sensitizers (metformin or thiazolidinediones) are used with insulin secretagogues, the dose of the secretagogue should be reduced to minimize the risk of hypoglycaemia 3 .
Sulfonylureas increase insulin secretion by binding to a high affinity receptor on the surface of islet beta cells of the pancreas 3 , and the Royal Australian College of General Practitioners and Diabetes Australia 18 recommend the use of sulfonylureas if a trial of healthy lifestyle and metformin failed to accomplish the required goals. The most significant adverse effect of sulfonylureas is hypoglycaemia 18 . Long acting sulfonylureas such as glibenclamide and glimperide have the potential to prolong hypoglycaemia in geriatric patients and in patients with renal impairment 25 . Therefore, glibizide and gliclazide, which are converted to inactive metabolites by the liver, are the sulfonylureas of choice in these patients 25 . The American Diabetes Association 13 recommends the early initiation of insulin therapy if an intervention of lifestyle changes in combination with metformin does not allow the person to achieve the target of HbA 1C <7%. Acarbose is used when blood glucose concentrations remain high after meals despite dietary modification 18 . Acarbose acts by inhibiting the digestion of carbohydrate thus slow the rate of glucose delivery into the circulation 18 . Acarbose is to be taken at the start of the meal and introduced slowly to avoid the impact of the side effects of flatulence and abdominal discomfort 3, 18 . If hypoglycaemia occurs in people taking acarbose, because of concurrent sulfonylurea or insulin treatment, glucose rather than other carbohydrates is required 8 Benefits Scheme, causes a rapid increase in pancreatic insulin secretion 18 . Repaglinide can be used as monotherapy or as dual therapy with metformin to control postprandial hyperglycaemia 18 . Diabetes Australia 18 recommends that repaglinide should not be used in combination with sulfonylureas. Glitinides as well as sulfonylureas can lead to weight gain so discussion of lifestyle management (exercise and food intake) is of benefit to minimize the adverse effect.
The thiazolidinediones are another class of oral hypoglycaemic medicines and include pioglitazone and rosiglitazone 8, 17 . These medicines are effective in lowering blood glucose concentration by reducing insulin resistance with their action as selective agonists for peroxisome profilator-activated receptor gamma. Both of these drugs can be used as dual therapy with metformin or sulfonylureas 18 . Pioglitazone could also be used in triple therapy with metformin and a sulfonylurea or in combination with insulin 18 . Contraindications to pioglitazone include moderate to severe cardiac failure 17 . Rosiglitazone is not approved in triple therapy with metformin and a sulfonylurea or in combination with insulin 18 . Pioglitazone is contraindicated in patients with moderate to severe heart failure and rosiglitazone is contraindicated in all classes of heart failure 17 . Rosiglitazone is not recommended in patients with known ischaemic heart disease, particularly in people taking nitrates 18 . These recommendations were approved after many years of studying the cardiovascular safety of rosiglitazone 26 .
Two groups of hypoglycaemic agents target the glucagon-like peptide (GLP-1) actions 3, 17 . GLP-1 enhances insulin secretion and inhibits glucagon secretion in a glucose dependent approach 8 . Fasting and postprandial glucose concentrations are reduced 3 . The GLP-1 'mimetics' are injected subcutaneously and bind to the GLP-1 receptor (e.g. exenatide, and liraglutide) 18 .
The GLP-1 enhancers, DPP4 inhibitors, are oral medications that slow the catabolism of endogenous GLP-1 17 . Sitagliptin, saxagliptin, and vildagliptin, are available in Australia
18
. The GLP-1 mimetics also aid weight loss and the DPP-4 inhibitors are generally weight neutral and improve post prandial control 18 . Sodium glucose co-transport (SGLT2) inhibitors (dapagliflozin, sergliflozin, and remogliflozin) increase glucose urinary excretion and lower plasma glucose concentrations in an insulin-independent mechanism 27 . The most frequently reported adverse effects in phase II and III trials are gastrointestinal (constipation, diarrhea, nausea, urinary frequency), urinary tract infections (UTIs) and vulvovaginal infections 27 . In a recent phase III clinical trial, urinary tract infections and genital infections were more frequently detected in the dapagliflozin group compared to the placebo group 27 .
When used as mono-therapy, metformin, acarbose, glitazones, GLP-1 mimetics and DPP-4 inhibitors will not cause hypoglycaemia 3, 17 . 18 . Insulin types and brands available in are listed in Table 2 .
Other Aspects of Management
Adverse effects may contribute to poor adherence 3 .
This confirms the importance of the patient's health beliefs in effective disease management 3 . For the management of Type 2 diabetes, the rate of adherence among patients to insulin administration was about 20% 28 . More than 20 studies published in the past few years found that compliance with oral hypoglycaemic medicines ranged from 65% to 85% 28 . Optimal diabetes care can be achieved if clinicians collaborate with patients in diabetes management, if healthcare systems support systematic patient response monitoring, and enhance treatment titration to achieve positive diabetes outcomes with minimal complications 29 .
The first step in achieving optimal diabetes outcomes is by knowing that not taking medications as directed is common in patients with diabetes mellitus 29 . Useful clinical approaches include a nonjudgmental assessment of medication-taking, clear explanations about how to use medications, simplified regimens, and scheduled followup visits to monitor progress and adjust treatment 29 . Such approaches can be used by health care providers and patients in a busy primary care setting 29 .
Diabetes self-management education (DSME) is considered to be an important part in improving patients' clinical outcomes 2, 8, 13 . Specific self-management addresses the following issues: self-monitoring of blood glucose (SMBG), hypoglycaemia, insulin injection devices, sick day rules, pre-pregnancy counselling, medications, meal planning, and exercise 8 .
The American Diabetes Association developed the National Standards for Diabetes Self-Management Education which are updated and published every year to define standards for the DSME 8 . Topics required in DSME are: diabetes disease process and treatment options, nutritional management, exercise, therapeutic effectiveness of medicines, monitoring of blood glucose, preventing, detecting and treating acute and chronic complications, goal setting to promote health and resolve problems, psychological and social adjustment, and preconception care for patients with diabetes during pregnancy 8, 13 .
It was found that diabetes mellitus costs the Australian Government around AUS$680 million per year which is considered a negative influence from the economic perspective as well as from the health wellbeing of the community population 30 . The National Diabetes Services Scheme (NDSS), which is an initiative of the Australian Government administered by Diabetes Australia, financially supports patients with diabetesrelated products and provides information and support services to people with diabetes 21 . 32 . To address this issue of uncertainty, the researchers used appropriate statistical methods to control the difference in baseline measurements 32 . There were also difficulties in retrieving final clinical data from general practitioners for some patients; however, the proportion of patients for whom final clinical data were missing was similar for the intervention and control groups (20% and 24%) respectively 32 . The duration of the study was only six months 32 . Further research is needed to clarify the sustainability of changes in disease control over time and the type and intensity of interventions which are most suitable clinically and are cost-effective 32 .
An approach to DSME is shown in the analytic framework (Figure 2) , which shows the relationships between the intervention, intermediate outcomes (knowledge, psychosocial mediators, and behaviours), and short-and long-term health and quality of life outcomes 33 . In the figure, ovals indicate interventions, rectangles with rounded corners represent short-term outcomes, and rectangles with squared corners refer to long-term outcomes 33 . Self-management education and education interventions can improve knowledge and clinical outcomes 33 .
CONCLUSION
This review of the literature has highlighted the importance of diabetes as a global health issue, as well as discussed therapeutic goals, pharmacologic treatment, and the impact of treatment on quality of life. Future studies should examine the adherence of prescribers to evidence based medicine at the pharmacological and lifestyle levels. Assessment of patients' knowledge about diabetes and their quality of life should also be incorporated into daily practice. Healthcare providers should also engage patients in self-management education to facilitate behaviour change, achieve better clinical and quality of life outcomes, and minimize costs related to treatment and complications. 
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